The bank points to the international Oral Wegovy rollout and coming trial results as near-term catalysts, while flagging its Q3 earnings view.
Recap by typeshit. Post by Investseekers on X.
Osbourne says any medicine can be misused and connects Ozempic to the body image struggles he had when he was younger.
A one-line stock move for the maker of Mounjaro and Zepbound, with no reason given for the gain.
29:53
Journalist Scott Carney argues in favor of gray-market peptides. Only the title is available, so watch for his full reasoning and treat any health claims with caution.
The company announced exclusive manufacturing rights across its needle-free peptide products. Terms aren't given here.
Zepbound added $4.9 billion in US sales and oral Foundayo made $98 million in its first quarter. Both companies report Q3 results on Oct. 29.
Kalkine ties the Canadian-listed company's move to its peptide therapy push, fresh funding and interest in the longevity market.
Loading…